Evidence map›Paper›PMID 34697160›Full record

ArticleIn vivo (Athens, Greece)

Importance of Compliance With Guidelines for the Prevention of Varicella-Zoster Virus Reactivation in Multiple Myeloma.

Yasukata Ohashi, Megumi Yatabe, Daisuke Niijima, Arina Imamura, Yoshiyuki Nagayama, Kentaro Otsuka, Yutaka Yachi, Hironori Ueno, Takahiro Yano, Nobuaki Mori and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yasukata OhashiDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan; yasu970554126@gmail.com.
Megumi YatabeDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Daisuke NiijimaDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Arina ImamuraDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Yoshiyuki NagayamaDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Kentaro OtsukaDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Yutaka YachiDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Hironori UenoDivision of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Takahiro YanoDivision of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Nobuaki MoriDepartment of General Internal Medicine and Infectious Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Koji HigaiDepartment of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
Akihiro YokoyamaDivision of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Tokyo Medical Center · JPNational Hospital Organization · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe importance of compliance with National Comprehensive Cancer Network (NCCN) guidelines for preventing varicella-zoster virus reactivation (VZVr) in multiple myeloma (MM) in a clinical setting has not been well investigated. PATIENTS AND

methodsWe retrospectively studied the clinical characteristics and outcomes of 118 patients with MM treated with proteasome inhibitors.

resultsThirty-nine episodes of VZVr were observed in 37 patients (VZVr group). The proportion of prophylactic antiviral prescriptions and compliance with antiviral prophylaxis based on the NCCN Clinical Practice guidelines was 76% and 30% in the VZVr group, and 88% and 74% in the non-VZVr group, respectively. Multivariate analysis showed that compliance with the NCCN guidelines was the only independent risk factor for VZVr (p=0.0017).

conclusionIt is important that prophylactic antivirals are prescribed for an appropriate duration of time to prevent the reactivation of VZV in compliance with existing guidelines.

Indexed as

Herpes ZosterMultiple MyelomaAcyclovirAntiviral AgentsHerpesvirus 3, HumanHumansRetrospective StudiesVirus ActivationAcyclovirAntiviral Agentscompliancemultiple myelomaNCCN guidelinesproteasome inhibitorsVaricella-zoster virus reactivation

Identifiers

PMID34697160
PMCPMC8627750
OpenAlexW3208970231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.